Beyond Air to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Core Insights - Beyond Air, Inc. is participating in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York, NY, with CEO Steve Lisi representing the company [1] - An on-demand webcast of the company's presentation will be available starting September 5, 2025, and management will be available for one-on-one meetings with investors [2] Company Overview - Beyond Air is a commercial-stage medical device and biopharmaceutical company focused on using nitric oxide (NO) to treat patients with respiratory illnesses, neurological disorders, and solid tumors [3] - The company has received FDA approval and CE Mark for its LungFit PH system, which treats term and near-term neonates with hypoxic respiratory failure [3] - Beyond Air is advancing other LungFit systems in clinical trials for severe lung infections, including viral community-acquired pneumonia and nontuberculous mycobacteria [3] Research and Development - The company has partnered with The Hebrew University of Jerusalem to develop a pre-clinical program for treating autism spectrum disorder and other neurological disorders [4] - Beyond Cancer, Ltd., an affiliate of Beyond Air, is exploring ultra-high concentrations of NO for targeting solid tumors in pre-clinical studies [4] Product Details - The LungFit system is a cylinder-free, phasic flow generator that can deliver NO from ambient air at concentrations ranging from 1 ppm to 80 ppm, designed to replace high-pressure NO cylinders [5] - LungFit can also deliver NO at concentrations above 80 ppm for treating severe acute lung infections in hospitals and chronic infections in home settings [6] - LungFit PH is approved for commercial use in the U.S., EU, and other countries, while other LungFit systems are for investigational use only [7]